Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Pelletier

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|January 12, 2023
A conserved SH3-like fold in diverse putative proteins tetramerizes into an oxidoreductase providing an antimicrobial resistance phenotypeClaudèle Lemay-St-Denis, Lorea Alejaldre, Zakaria Jemouai, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate ReductasesJacynthe L Toulouse, Genbin Shi, Claudèle Lemay-St-Denis, et al.
ACS Omega|August 29, 2019
Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric AnaloguesJacynthe L Toulouse, Brahm J Yachnin, Edward H Ruediger, et al.
Scientific Reports|November 20, 2021
Author Correction: Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteinsMaryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, et al.
Scientific Reports|November 9, 2021
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteinsMaryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2025
PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapyAndres Chang, Adam N Pelletier, Donald J McGuire, et al.
American Journal of Human Genetics|February 12, 2011
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiencySiddharth Banka, Henk J Blom, John Walter, et al.
Nature Medicine|February 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapyAarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, et al.
The Analyst|July 12, 2021
Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individualsAbdelhadi Djaileb, Maryam Hojjat Jodaylami, Julien Coutu, et al.
Faraday Discussions|August 23, 2024
Enzyme evolution, engineering and design: mechanism and dynamics: general discussionCarlos Acevedo-Rocha, Lukasz Berlicki, Uwe T Bornscheuer, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|January 12, 2023
A conserved SH3-like fold in diverse putative proteins tetramerizes into an oxidoreductase providing an antimicrobial resistance phenotypeClaudèle Lemay-St-Denis, Lorea Alejaldre, Zakaria Jemouai, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate ReductasesJacynthe L Toulouse, Genbin Shi, Claudèle Lemay-St-Denis, et al.
ACS Omega|August 29, 2019
Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric AnaloguesJacynthe L Toulouse, Brahm J Yachnin, Edward H Ruediger, et al.
Scientific Reports|November 20, 2021
Author Correction: Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteinsMaryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, et al.
Scientific Reports|November 9, 2021
Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteinsMaryam Hojjat Jodaylami, Abdelhadi Djaïleb, Pierre Ricard, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2025
PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapyAndres Chang, Adam N Pelletier, Donald J McGuire, et al.
American Journal of Human Genetics|February 12, 2011
Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiencySiddharth Banka, Henk J Blom, John Walter, et al.
Nature Medicine|February 12, 2026
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapyAarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, et al.
The Analyst|July 12, 2021
Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individualsAbdelhadi Djaileb, Maryam Hojjat Jodaylami, Julien Coutu, et al.
Faraday Discussions|August 23, 2024
Enzyme evolution, engineering and design: mechanism and dynamics: general discussionCarlos Acevedo-Rocha, Lukasz Berlicki, Uwe T Bornscheuer, et al.
Pageof 16